Calluna Pharma is focused on developing innovative therapeutics that address the underlying causes of inflammation and fibrosis, leveraging over 30 years of research. The company employs a unique approach that targets upstream innate immune amplifiers, specifically the S100A4 protein, which plays a critical role in the inflammatory and fibrotic responses associated with various chronic diseases. By modulating disease-associated signaling pathways, Calluna Pharma aims to create first-in-class clinical-stage antibodies that can effectively treat conditions such as idiopathic pulmonary fibrosis, systemic sclerosis, and rheumatoid arthritis, among others. This strategy not only seeks to improve patient outcomes but also to fulfill significant unmet medical needs in the field of chronic inflammatory and fibrotic diseases.

In addition to targeting S100A4, Calluna Pharma is also developing therapeutics aimed at neutralizing oxidized phospholipids (oxPLs), which are implicated in harmful inflammation across a range of immunological conditions. By addressing the effects of oxPLs, the company aims to reduce immune system activation and enhance the quality of life for patients suffering from diseases like rheumatoid arthritis and severe respiratory conditions. The combination of these targeted approaches positions Calluna Pharma as a pioneering force in the biotech industry, with a robust pipeline of therapeutics designed to tackle the root causes of inflammation and fibrosis, ultimately transforming treatment options for patients worldwide.

Norway

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal.

We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases. 


Calluna Pharma

Company Details